SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00426296 |
Recruitment Status
: Unknown
Verified October 2007 by Clinical Alliance for Research & Education - Infectious Diseases, LLC..
Recruitment status was: Recruiting
First Posted
: January 24, 2007
Last Update Posted
: November 1, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections Lipodystrophy | Drug: atazanavir (Reyataz) Drug: ritonavir (Norvir) | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks |
Study Start Date : | August 2006 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen
- Viral load <50 copies/ml
Exclusion Criteria:
- Viral load >50 copies/ml
- Having taken more than one antiretroviral regimen

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00426296
Contact: Richard A. Elion, MD | drrelion@aol.com |
United States, District of Columbia | |
Whitman-Walker Clinic | Recruiting |
Washington, District of Columbia, United States | |
Contact: Richard Elion, MD drrelion@aol.com | |
Principal Investigator: Richard A Elion, MD |
Principal Investigator: | Richard A Elion, MD | Whitman-Walker Clinic |
ClinicalTrials.gov Identifier: | NCT00426296 History of Changes |
Other Study ID Numbers: |
COL102060 |
First Posted: | January 24, 2007 Key Record Dates |
Last Update Posted: | November 1, 2007 |
Last Verified: | October 2007 |
Keywords provided by Clinical Alliance for Research & Education - Infectious Diseases, LLC.:
HIV Reyataz atazanavir Norvir |
ritonavir Boosted Lipodystrophy Treatment Experienced |
Additional relevant MeSH terms:
HIV Infections Lipodystrophy Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Skin Diseases, Metabolic Skin Diseases Lipid Metabolism Disorders Metabolic Diseases Ritonavir |
Atazanavir Sulfate Abacavir HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors |